ANTIRETROVIRAL THERAPY OPTIMISATION STRATEGIES IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS:

A DECISIVE TASK FOR HOSPITAL PHARMACISTS

Authors: Rubio-Calvo D¹, Gutiérrez-Lorenzo M¹, Urda-Romacho J¹, Pinto-Nieto CM¹ Castro-Vida MA¹ 1: Agencia Pública Sanitaria Poniente, Almería, Hospital pharmacy service

4CPS-376

BACKGROUND AND IMPORTANCE

Antiretroviral therapy (ART) for Human immunodeficiency virus (HIV) cause a significative economic impact in health systems worldwide. To minimize such impact is crucial to optimize these therapies.

AIM AND OBJECTIVES

- Identify patients who could benefit from ART simplification from Dolutegravir/Abacavir/Lamivudine to Dolutegravir/Lamivudine (DTG/ABC/3TC and DTG/3TC Respectively)
- Analyze the economic impact of simplifying.

MATERIAL AND METHODS


DESING: Prospective experimental study **PARTICIPANTS**: HIV patients treated with DTG/ABC/3TC

SIMPLIFICATION CRITERIA

- 1. Active ART with DTG/ABC/3TC for at 3. No prior ART failures least 6 months
- 2. Undetectable plasmatic viral load (VL) 4. Optimal adherence: ≥95% score for at least 6 months (< 50 copies/ml) (days treatment was collected on time)

Other relevant criteria: adverse effects (AE) derived from ART were registered however they were not an essential item for simplification

RESULTS



CONCLUSIONS AND RELEVANCE

- Hospital pharmacist role is fundamental for treatment optimization
- ART simplification implies an economic saving and a potential reduction of AE







Contact: Daniel.rubio@ephpo.es